Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration
By
- AMS
posted
Jan 06, 2020 09:32 AM
0
Recommend
Volume 32, Issue 7
, November 2021, Page 783-787
.
0 comments
0 views
Permalink
Related Content
The impact of active vitamin D administration on the clinical outcomes of acne vulgaris
- AMS
Added Jan 04, 2020
Blog Entry
Concomitant atopic dermatitis and psoriasis – a retrospective review
- AMS
Added Dec 18, 2019
Blog Entry
Prevalence and treatment outcomes of skin infections among elderly population: a retrospective cross-sectional study
- AMS
Added Mar 06, 2020
Blog Entry
Efficacy of fractional carbon dioxide laser therapy for burn scars: a meta-analysis
- AMS
Added Dec 23, 2019
Blog Entry
Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries
- AMS
Added Mar 06, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic